Siddiqui, M. S.
Lai, Z. M.
Spain, L.
Greener, V.
Turajlic, S.
Larkin, J.
Morganstein, D. L.
Article History
Received: 8 March 2020
Accepted: 13 May 2020
First Online: 24 May 2020
Compliance with ethical standards
:
: MS, LZ, LS and VG have no interests to declare. DLM has received speaker and advisory fees from BMS, MSD and Roche. JL has received Institutional research support from BMS, MSD, Novartis, Pfizer, Achilles Therapeutics, Roche, Nektar Therapeutics, Covance, Immunocore, Pharmacyclics, Aveo and Consultancy from Achilles, AZ, Boston Biomedical, BMS, Eisai, EUSA Pharma, GSK, Ipsen, Imugene, Incyte, iOnctura, Kymab, Merck Serono, MSD, Nektar, Novartis, Pierre Fabre, Pfizer, Roche/Genentech, Secarna, Vitaccess and support from NIHR RM/ICR Biomedical Research Centre for cancer. ST is funded by Cancer Research UK (grant reference number C50947/A18176), the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden Hospital and Institute of Cancer Research (grant reference number A109), the Kidney and Melanoma Cancer Fund of The Royal Marsden Cancer Charity, The Rosetrees Trust (grant reference number A2204), and Ventana Medical Systems Inc (Grant reference numbers 10467 and 10530). ST has received speaking fees from Roche and Astra Zeneca. ST has the following patents filed: Indel mutations as a therapeutic target and predictive biomarker PCTGB2018/051892 and PCTGB2018/051893 and Clear Cell Renal Cell Carcinoma Biomarkers P113326GB.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: As all data was obtained as part of routine clinical care and collected retrospectively in an anonymised fashion consent was not required.